InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.37
(
-0.27%
)
Bitcoin
61,299.82
(
0.83%
)
Post# of 177
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

oc631

Send PM Follow Ignore
Followers 15
Posts 1730
Boards Moderated 0
Alias Born 08/12/2007

oc631

Re: hptaxis post# 139

Thursday, 09/01/2011 8:30:13 AM

Thursday, September 01, 2011 8:30:13 AM

Post# of 177
Welcome aboard.

I'm focused on the efficacy of PSI-7977/SOC in GT2/GT3 patients going into AASLD this November. The company continues to shorten the treatment duration (with one cohort down to 8 weeks) in what the CEO calls a game of limbo. At some point the drug combo will lose the 100% efficacy seen at 12 weeks but if all patients in the 8 week cohort achieve SVR's it would be unprecedented and the FDA may be willing to bring the drug to market early for the underserved GT2/GT3 market. There seems to be no safety or tolerability issues with this drug.

If this occurs even the most bullish analyst estimates may fall short next year.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up